Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mineralization Clear all

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Osteoporosis, Ovarian Carcinoma
Interventions: Laboratory Biomarker Analysis, Zoledronic Acid; Other · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 95
States / cities: Scottsdale, Arizona • Tucson, Arizona • Burbank, California + 76 more

Conditions: Vascular Calcification, Atherosclerosis, Bone Density
Interventions: CT of the bones; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Postmenopausal Bone Loss
Interventions: Arzoxifene, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Juvenile Rheumatoid Arthritis
Interventions: Calcium carbonate; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 18 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: UConn Health; Other
Eligibility: 40 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hyperphenylalaninemia, Phenylketonuria
Interventions: Sapropterin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Osteopenia, Osteoporosis
Interventions: Zoledronate, Zoledronate placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteopenia
Interventions: bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium; Drug · Dietary Supplement
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis, Osteopenia, Vitamin D Deficiency, Hypoparathyroidism, Hypercalciuria, Hypercalcemia
Interventions: Vitamin D; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years to 66 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Exercise, Healthy
Interventions: Osteogenic Index Optimized Exercise Training Program; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 40 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Lawrence, Kansas • Pittsburgh, Pennsylvania

Conditions: Osteoporosis, Hip Fracture
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 2,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Eureka, California • La Mesa, California + 24 more

Conditions: Osteoporosis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 65 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Osteodystrophy
Interventions: Not listed
Lead sponsor: Hartmut Malluche, MD; Other
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness
Interventions: Vitamin D3, Physical Activity; Drug · Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Spinal Cord Injury
Interventions: Exoskeleton-Assisted Walking (EAW), Sham Transcutaneous Spinal Cord Stimulation (tSCS), Active Transcutaneous Spinal Cord Stimulation (tSCS); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Bone Mineral Density, Body Fat Distribution, Insulin Homeostasis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 10 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hyperparathyroidism, Secondary
Interventions: Etelcalcetide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 51
States / cities: Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more

Conditions: Postmenopausal Osteoporosis
Interventions: AGA2118, Placebo; Drug · Other
Lead sponsor: Angitia Biopharmaceuticals; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more

Conditions: Endometrial Cancer, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 15,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis
Interventions: Parathyroid hormone, Alendronate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 46 Years to 85 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: To Assess the Changes in Markers of Bone Turnover Over a Six Month Period After Epidural Steroid Inject, To Assess the Changes in Bone Mineral Density
Interventions: Triamcinilone (kenalog); Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions: Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Gainesville, Florida • Tampa, Florida

Search by objective public record fields.

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Association of Bone Quality and Quantity With Vascular Calcification

Effects of Arzoxifene on Bone Mass and the Uterus

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

Anastrozole and Letrozole

Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Does Treatment of Hypovitaminosis D Increase Calcium Absorption?

Bone and Body Composition Adaptations to Physical Training

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Does Gender Play a Role in Bone-mineral Density Measurement Precision?

Renal Osteodystrophy: A Fresh Approach

Vitamin D and Physical Activity on Bone Health

Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation: Effect on Imaging and Serum Biomarkers of Skeletal Muscle Mass and Bone Strength.

The Bone-Fat-Pancreas Axis in Children

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

Bone Mineral Density and Subsequent Cancer Risk

Effects of Parathyroid Hormone in Men With Osteoporosis

Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Testosterone Plus Finasteride Treatment After Spinal Cord Injury